Hosted on MSN3mon
Targeting novel molecular mechanisms may repair damaged DNA in cancer cells
On one hand, it represses PARP1 catalytic activity and associated DNA damage repair. On the other hand, it also protects cells from overconsuming nicotinamide adenine dinucleotide—a coenzyme ...
The Scientist1y
Optimizing Gene Editing with PARP1 CRISPR Plasmids
Santa Cruz Biotechnology, Inc.’s PARP1 CRISPR plasmids are optimized for research use that can lead to disease treatment advances. For example, the PARP1 homology-directed repair (HDR) plasmid ...
Business Wire17d
Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα ...
Synnovation’s lead candidate and potentially best-in-class PARP1 selective program, SNV1521, entered a Phase I trial in January of 2024. The SNV4818 Phase I trial, which is being led by Timothy ...
pharmaphorum15d
Perlmutter's Eikon raises $351m in major financing round
Eikon Therapeutics has added to its already copious cash reserves with a $351 million fourth-round financing to fund a ...
The Scientist2y
Setting Better Traps for PARP Inhibitors
The PARP protein family comprises 17 members, but PARP1 and PARP2 are the main proteins involved in DNA repair. Both proteins regulate the DDR network, but PARP1 also regulates transcription and ...
Nature1mon
Expansion and evolution of cell death programmes
Multiple pathways of non-apoptotic cell death have recently been described, namely autophagic cell death, necroptosis and poly (ADP–ribose) polymerase-1 (PARP1)-mediated cell death. Emerging ...
pharmaphorum1y
Merck signs €1.4bn cancer alliance with China’s Hengrui
Merck gets exclusive rights to Hengrui’s PARP1 drug HRS-1167 outside China under the terms of the agreement, and also picks up an option for an ex-China license to SHR-A1904, an ADC directed at ...